- Home
- MNOV vs ARMP Comparison
MNOV vs ARMP Comparison
Compare MNOV & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- ARMP
- Stock Information
- Founded
- MNOV 2000
- ARMP N/A
- Country
- MNOV United States
- ARMP United States
- Employees
- MNOV N/A
- ARMP N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNOV Health Care
- ARMP Health Care
- Exchange
- MNOV Nasdaq
- ARMP Nasdaq
- Market Cap
- MNOV 60.3M
- ARMP 125.7M
- IPO Year
- MNOV 2005
- ARMP N/A
- Fundamental
- Price
- MNOV $1.66
- ARMP $4.91
- Analyst Decision
- MNOV Strong Buy
- ARMP Strong Buy
- Analyst Count
- MNOV 2
- ARMP 1
- Target Price
- MNOV $7.00
- ARMP $9.00
- AVG Volume (30 Days)
- MNOV 2.7M
- ARMP 736.0K
- Earning Date
- MNOV 11-14-2025
- ARMP 11-07-2025
- Dividend Yield
- MNOV N/A
- ARMP N/A
- EPS Growth
- MNOV N/A
- ARMP N/A
- EPS
- MNOV N/A
- ARMP N/A
- Revenue
- MNOV $134,599.00
- ARMP $6,868,000.00
- Revenue This Year
- MNOV N/A
- ARMP $8.43
- Revenue Next Year
- MNOV N/A
- ARMP N/A
- P/E Ratio
- MNOV N/A
- ARMP N/A
- Revenue Growth
- MNOV N/A
- ARMP 84.67
- 52 Week Low
- MNOV $1.13
- ARMP $0.90
- 52 Week High
- MNOV $2.55
- ARMP $16.34
- Technical
- Relative Strength Index (RSI)
- MNOV 81.50
- ARMP 57.18
- Support Level
- MNOV $1.17
- ARMP $4.88
- Resistance Level
- MNOV $1.22
- ARMP $5.59
- Average True Range (ATR)
- MNOV 0.08
- ARMP 1.21
- MACD
- MNOV 0.03
- ARMP 0.04
- Stochastic Oscillator
- MNOV 62.12
- ARMP 16.68
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.